OptiNose Raises $37 Million in Series D Funding Led by Fidelity

New Capital Supports Preparation for 2018 Commercialization of Lead Product OPN-375

YARDLEY, PA, May 9, 2017 – OptiNose, a commercial-stage ENT / Allergy specialty pharmaceutical company, today announced that it has closed a $37 million Series D financing led by Fidelity Management and Research Company with participation from Avista Capital Partners, Entrepreneurs Fund and other current investors. OptiNose will use the additional capital to fund commercial readiness for the launch of its lead product candidate, OPN-375, in the United States.

Download full press release here